Back to search results

Ruxolitinib for Preventing Graft-Versus-Host Disease After Stem Cell Transplant

This study is looking at whether the drug ruxolitinib, given with other medications like cyclophosphamide, mycophenolate mofetil, and tacrolimus, can help prevent graft-versus-host disease (GVHD) in people with blood cancers (hematologic malignancies) who are getting a stem cell transplant. GVHD is a serious complication where the transplanted cells attack the patient's body. Researchers want to see which approach is better at preventing chronic GVHD for up to one year after the transplant. You may be able to join if you are at least 18 years old and have a blood cancer that is in remission. The study aims to enroll 40 participants, but its current status is unclear.

Study design
This interventional study aims to enroll 40 participants to compare two different approaches for preventing GVHD.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to assess cGVHD-free survival for one year after the stem cell transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07359859

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Recruiting
PHASE2Ages 18+InterventionalPrevention
Memorial Sloan Kettering Cancer Center
~40 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:CyclophosphamideMycophenolate MofetilRuxolitinibTacrolimus

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
assess cGVHD-free survival
Measured over 1 year post-HCT

Conditions

Hematologic Malignancies

Explore related trials

Malignant neoplasm of lymphoid, hematopoietic and/or related tissue

NCT07359859

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)

    Rockville Centre, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

    Commack, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Doris Ponce, MD, MS · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Doris Ponce, MD, MS
[email protected]
646-608-3739
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥18- years-old at time of consent
Diagnosis: hematologic malignancy in morphologic remission (blasts \<5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed. Patients with lymphoma must have a complete or partial response
Donor: related or unrelated 7-8/8 HLA-matched or related haploidentical
Karnofsky score ≥ 70%
Female subjects of childbearing potential (\<50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months.
For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug

Exclusion

Recipient of CD34+ selected or engineered stem cell graft
Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin)
Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 5 years. Exceptions include adequately treated localized non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance.
Severely impaired renal function defined by serum creatinine \> 2mg/dL, renal dialysis requirement.
Use of investigational agent within 14 days pre-HCT
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Uncontrolled psychiatric illness
Female patient who is pregnant or breastfeeding
Known allergy or sensitivity to ruxolitinib

What this trial measures

  • assess cGVHD-free survival1 year post-HCT

    Chronic GVHD-free survival is defined as moderate-to-severe cGVHD requiring systemic immunosuppression treatment from the date of allo-HCT to first occurrence with follow-up through 12 months post-HCT or death.